Among them, conjugate 9a produced significant increase in life span (200-293%) in mice bearing ip and ic implanted L1210 lymphoic leukemia at a total dose of 400-500 mg (406- 508 pmol/kg). Significant schedule dependence was not observed when the conjugate was Riven ip once daily on day 1, days 1, 5, and 9, and days 1-5. The new conjugates are water soluMe by sonication.
